RespireRx Pharmaceuticals Inc. Share Price
Equities
RSPI
US7612273059
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.00085 USD | -2.30% | 0.00% | 0.00% |
Sales 2021 | - | Sales 2022 | - | Capitalization | 289K 23.03M |
---|---|---|---|---|---|
Net income 2021 | -3M -239M | Net income 2022 | -2M -160M | EV / Sales 2021 | - |
Net Debt 2021 | 2.08M 166M | Net Debt 2022 | 2.71M 216M | EV / Sales 2022 | - |
P/E ratio 2021 |
-0.29
x | P/E ratio 2022 |
-0.06
x | Employees | 2 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 93.37% |
1 day | -2.30% | ||
Current month | -10.00% | ||
1 month | -10.00% | ||
3 months | -43.75% | ||
6 months | +28.57% |
Managers | Title | Age | Since |
---|---|---|---|
Arnold Lippa
CEO | Chief Executive Officer | 77 | 21/03/13 |
Jeff Margolis
DFI | Director of Finance/CFO | 68 | 21/03/13 |
Richard Purcell
CTO | Chief Tech/Sci/R&D Officer | 63 | 14/10/14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Arnold Lippa
CEO | Chief Executive Officer | 77 | 21/03/13 |
Director/Board Member | - | 21/03/23 | |
Jeff Margolis
DFI | Director of Finance/CFO | 68 | 21/03/13 |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 0.00085 | -2.30% | 3,727,442 |
25/04/24 | 0.00087 | +2.35% | 420,000 |
24/04/24 | 0.00085 | +6.25% | 464,222 |
23/04/24 | 0.0008 | -11.11% | 576,203 |
22/04/24 | 0.0009 | 0.00% | 5,336,935 |
Delayed Quote OTC Markets, April 26, 2024 at 08:47 pm
More quotes1st Jan change | Capi. | |
---|---|---|
0.00% | 658K | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- RSPI Stock